多発性筋炎の世界市場レポート 2025年

多発性筋炎市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は6.2%で22億3,000万米ドルに成長します。予測期間中の成長は、遠隔医療の拡大、遠隔モニタリングの利用拡大、免疫抑制剤の利用拡大、幹細胞治療の増加、バイオシミラーの採用拡大などに起因しています。この期間の主な動向としては、創薬における人工知能の統合、標的治療の進展、新規免疫調節薬の開発、再生医療研究の高まり、ビッグデータの統合などが挙げられます。

自己免疫疾患の有病率の増加は、多発性筋炎市場の成長を促進すると予想されます。自己免疫疾患は、身体の免疫システムが誤って自身の健康な細胞、組織、臓器を攻撃し、炎症や損傷を引き起こすことで発生します。このような疾患の有病率は、過剰な免疫反応を引き起こし、自己の組織を攻撃しやすくする特定の遺伝子変異のために上昇しています。このような遺伝的素因に、感染症、ストレス、ライフスタイルの選択などの環境因子が加わり、自己免疫疾患の罹患率が増加しています。多発性筋炎は、免疫系の機能不全がどのように筋肉の炎症を引き起こすかを実証することで、自己免疫疾患の理解に貢献し、関連疾患のメカニズムや潜在的な治療法に関する洞察を提供します。例えば、2024年11月、ドイツを拠点とする組織であるVersorgungsatlas.deは、2022年に7,324万1,305人の被保険者のうち、630万4,340人が少なくとも1つの自己免疫疾患と診断されたと報告しました。このように、自己免疫疾患の有病率の増加が多発性筋炎市場を牽引しています。

経口薬に対する需要の高まりは、多発性筋炎市場の成長をさらに加速させると予想されます。経口薬とは、錠剤、カプセル剤、液剤などの形態で口から服用する薬剤のことで、消化器官から吸収されます。経口薬への嗜好が高まっているのは、その利便性、使いやすさ、非侵襲性によるもので、注射や他の投薬形態よりも好ましい選択肢となっています。多発性筋炎は、筋肉の炎症を抑え、免疫系を調整し、筋肉機能を改善する経口薬で治療されることが多く、症状の緩和や病気の進行防止に役立っています。例えば、2022年10月、米国疾病予防管理センター（CDC）は、経口抗ウイルス薬の調剤数が、2022年4月24日から5月21日の間の10万人当たり643件から、2022年7月31日から8月28日の間の10万人当たり1,012件へと、57％増加したと報告しています。このような経口薬の需要増加が多発性筋炎市場の成長に寄与しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の多発性筋炎PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の多発性筋炎市場：成長率分析
• 世界の多発性筋炎市場の実績：規模と成長, 2019-2024
• 世界の多発性筋炎市場の予測：規模と成長, 2024-2029, 2034F
• 世界の多発性筋炎総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の多発性筋炎市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 特発性多発性筋炎
• 皮膚筋炎
• 封入体筋炎
• 重複性筋炎症候群
• 世界の多発性筋炎市場：診断別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 身体検査
• 筋生検
• 筋電図検査（EMG）
• 血液検査
• 磁気共鳴画像法（MRI）
• 世界の多発性筋炎市場：治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 免疫抑制剤
• 免疫グロブリン
• コルチコステロイド
• アルキル化剤
• モノクローナル抗体
• 世界の多発性筋炎市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オフライン
• オンライン
• 世界の多発性筋炎市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• オンライン薬局
• 小売薬局
• 世界の多発性筋炎市場：タイプ別サブセグメンテーション、特発性多発性筋炎、実績と予測, 2019-2024, 2024-2029F, 2034F
• 免疫介在性多発性筋炎
• ウイルス関連多発性筋炎
• 世界の多発性筋炎市場：タイプ別サブセグメンテーション、皮膚筋炎、実績と予測, 2019-2024, 2024-2029F, 2034F
• 古典的な皮膚筋炎
• アミオパシー性皮膚筋炎
• 若年性皮膚筋炎
• 世界の多発性筋炎市場：タイプ別サブセグメンテーション、封入体筋炎、実績と予測, 2019-2024, 2024-2029F, 2034F
• 散発性封入体筋炎
• 遺伝性封入体ミオパチー
• 世界の多発性筋炎市場：タイプ別サブセグメンテーション、重複性筋炎症候群、実績と予測, 2019-2024, 2024-2029F, 2034F
• 全身性エリテマトーデス（SLE）の多発性筋炎
• 関節リウマチ（RA）の多発性筋炎
• 全身性強皮症の多発性筋炎
• 混合性結合組織病（MCTD）の多発性筋炎

第7章 地域別・国別分析

• 世界の多発性筋炎市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の多発性筋炎市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 多発性筋炎市場：競合情勢
• 多発性筋炎市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• GlaxoSmithKline plc
• Merck & Co. Inc.
• C.H. Boehringer Sohn AG & Co. KG
• Regeneron Pharmaceuticals Inc.
• Astellas Pharma Inc.
• Fresenius SE & Co. KGaA
• UCB S.A.
• Reliance Life Sciences Private Limited
• ARUP Laboratories
• Teva Pharmaceuticals USA Inc.
• Kezar Life Sciences Inc.
• Argenx SE
• Mallinckrodt Pharmaceuticals plc
• Mitsubishi Tanabe Pharma Corporation
• ViiV Healthcare Limited

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 多発性筋炎市場2029：新たな機会を提供する国
• 多発性筋炎市場2029：新たな機会を提供するセグメント
• 多発性筋炎市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Polymyositis is a chronic inflammatory myopathy that causes progressive muscle weakness, primarily affecting the skeletal muscles. It results from an autoimmune response in which the body's immune system mistakenly attacks muscle fibers, leading to inflammation, degeneration, and weakness.

The main types of polymyositis include idiopathic polymyositis, dermatomyositis, inclusion body myositis, and overlapping myositis syndromes. Idiopathic polymyositis is a rare muscle disease characterized by weakness and inflammation, typically treated with corticosteroids. Diagnosis is made through various methods, including physical examination, muscle biopsy, electromyography (EMG), blood tests, and magnetic resonance imaging (MRI). Treatments for the condition include immunosuppressants, immunoglobulins, corticosteroids, alkylating agents, monoclonal antibodies, and other medications. These treatments are distributed through various channels, such as offline and online, and are utilized by different end users, including hospital pharmacies, online pharmacies, and retail pharmacies.

The polymyositis market research report is one of a series of new reports from The Business Research Company that provides polymyositis market statistics, including the polymyositis industry global market size, regional shares, competitors with the polymyositis market share, detailed polymyositis market segments, market trends, and opportunities, and any further data you may need to thrive in the polymyositis industry. This polymyositis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The polymyositis market size has grown strongly in recent years. It will grow from $1.65 billion in 2024 to $1.75 billion in 2025 at a compound annual growth rate (CAGR) of 6.4%. The growth during the historic period can be attributed to increased access in developing regions, greater use of prednisone, the rising popularity of methotrexate for managing symptoms, a growing reliance on TNF inhibitors, and an increase in the use of antibody testing.

The polymyositis market size is expected to see strong growth in the next few years. It will grow to $2.23 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth during the forecast period can be attributed to the expansion of telemedicine, increased use of remote monitoring, growing use of immunosuppressants, a rise in stem cell therapy, and increased adoption of biosimilars. Key trends during this period include the integration of artificial intelligence in drug discovery, advancements in targeted therapies, the development of novel immunomodulators, rising research in regenerative medicine, and the integration of big data.

The increasing prevalence of autoimmune diseases is expected to drive the growth of the polymyositis market. Autoimmune diseases occur when the body's immune system mistakenly attacks its own healthy cells, tissues, or organs, causing inflammation and damage. The prevalence of these conditions is rising due to certain genetic variants that can trigger an overactive immune response, making individuals more likely to attack their own tissues. This genetic predisposition, combined with environmental factors such as infections, stress, and lifestyle choices, contributes to the growing incidence of autoimmune diseases. Polymyositis contributes to the understanding of autoimmune diseases by demonstrating how immune system dysfunction causes muscle inflammation, providing insights into the mechanisms of related conditions and potential treatments. For example, in November 2024, Versorgungsatlas.de, a Germany-based organization, reported that in 2022, among 73,241,305 insured individuals, 6,304,340 were diagnosed with at least one autoimmune disease, reflecting a raw prevalence rate of 8.61%. As such, the increasing prevalence of autoimmune diseases is driving the polymyositis market.

The rising demand for oral drugs is expected to further accelerate the growth of the polymyositis market. Oral drugs are medications taken by mouth in the form of tablets, capsules, or liquids, which are absorbed through the digestive system. The growing preference for oral drugs is due to their convenience, ease of use, and non-invasive nature, making them a preferred option over injections or other forms of medication delivery. Polymyositis is often treated with oral drugs that help reduce muscle inflammation, regulate the immune system, and improve muscle function, which helps alleviate symptoms and prevent disease progression. For instance, in October 2022, the Centers for Disease Control and Prevention (CDC) reported a 57% increase in the dispensing of oral antivirals, from 643 per 100,000 persons between April 24 and May 21, 2022, to 1,012 per 100,000 persons between July 31 and August 28, 2022. This increase in demand for oral drugs is contributing to the growth of the polymyositis market.

Companies operating in the polymyositis market are focusing on innovative therapies such as stem cell therapy to improve treatment outcomes and slow disease progression. Stem cell therapy involves using umbilical cord-derived stem cells for regenerative treatments. These stem cells have strong immunomodulatory and anti-inflammatory properties, making them a promising option for treating autoimmune diseases such as polymyositis. For example, in December 2024, RESTEM, a U.S.-based clinical-stage biotechnology company, received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for its stem cell program, which uses umbilical cord outer lining stem cells (ULSCs) to treat polymyositis and Dermatomyositis. This therapy works by regulating the immune system and reducing muscle inflammation. Early trials have shown promising safety and efficacy, with the potential to reduce dependency on steroids.

Major players in the polymyositis market are Pfizer Inc., F. Hoffmann-La Roche AG, Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Merck & Co. Inc., C.H. Boehringer Sohn AG & Co. KG, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Fresenius SE & Co. KGaA, UCB S.A., Reliance Life Sciences Private Limited, ARUP Laboratories, Teva Pharmaceuticals USA Inc., Kezar Life Sciences Inc., Argenx SE, Mallinckrodt Pharmaceuticals plc, Mitsubishi Tanabe Pharma Corporation, ViiV Healthcare Limited.

North America was the largest region in the polymyositis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in polymyositis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the polymyositis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The polymyositis market consists of revenues earned by entities by providing services such as diagnosis and testing services, pharmacological treatment services, physical therapy and rehabilitation services, and occupational therapy services. The market value includes the value of related goods sold by the service provider or included within the service offering. The polymyositis market also includes sales of anti-inflammatory and pain management medications, biologic therapies, intravenous immunoglobulin (IVIG) therapy, and plasmapheresis (plasma exchange) products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Polymyositis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on polymyositis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for polymyositis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The polymyositis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Idiopathic Polymyositis; Dermatomyositis; Inclusion Body Myositis; Overlapping Myositis Syndromes
• 2) By Diagnosis: Physical Examination; Muscle Biopsy; Electromyography (EMG); Blood Tests; Magnetic Resonance Imaging (MRI)
• 3) By Treatment: Immunosuppressant; Immunoglobulins; Corticosteroids; Alkylating agents; Monoclonal Antibodies
• 4) By Distribution Channel: Offline; Online
• 5) By End User: Hospital pharmacy; Online pharmacy; Retail pharmacy
• Sub Segments:
• 1) By Idiopathic Polymyositis: Immune-Mediated Polymyositis; Virus-Associated Polymyositis
• 2) By Dermatomyositis: Classic Dermatomyositis; Amyopathic Dermatomyositis; Juvenile Dermatomyositis
• 3) By Inclusion Body Myositis: Sporadic Inclusion Body Myositis; Hereditary Inclusion Body Myopathy
• 4) By Overlapping Myositis Syndromes:Polymyositis with Systemic Lupus Erythematosus (SLE); Polymyositis with Rheumatoid Arthritis (RA); Polymyositis with Systemic Sclerosis; Polymyositis with Mixed Connective Tissue Disease (MCTD)
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Bristol-Myers Squibb Company; AstraZeneca plc; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Polymyositis Market Characteristics

3. Polymyositis Market Trends And Strategies

4. Polymyositis Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Polymyositis Growth Analysis And Strategic Analysis Framework

• 5.1. Global Polymyositis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Polymyositis Market Growth Rate Analysis
• 5.4. Global Polymyositis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Polymyositis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Polymyositis Total Addressable Market (TAM)

6. Polymyositis Market Segmentation

• 6.1. Global Polymyositis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Idiopathic Polymyositis
• Dermatomyositis
• Inclusion Body Myositis
• Overlapping Myositis Syndromes
• 6.2. Global Polymyositis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Physical Examination
• Muscle Biopsy
• Electromyography (EMG)
• Blood Tests
• Magnetic Resonance Imaging (MRI)
• 6.3. Global Polymyositis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immunosuppressant
• Immunoglobulins
• Corticosteroids
• Alkylating agents
• Monoclonal Antibodies
• 6.4. Global Polymyositis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Offline
• Online
• 6.5. Global Polymyositis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital pharmacy
• Online pharmacy
• Retail pharmacy
• 6.6. Global Polymyositis Market, Sub-Segmentation Of Idiopathic Polymyositis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immune-Mediated Polymyositis
• Virus-Associated Polymyositis
• 6.7. Global Polymyositis Market, Sub-Segmentation Of Dermatomyositis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Classic Dermatomyositis
• Amyopathic Dermatomyositis
• Juvenile Dermatomyositis
• 6.8. Global Polymyositis Market, Sub-Segmentation Of Inclusion Body Myositis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Sporadic Inclusion Body Myositis
• Hereditary Inclusion Body Myopathy
• 6.9. Global Polymyositis Market, Sub-Segmentation Of Overlapping Myositis Syndromes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Polymyositis with Systemic Lupus Erythematosus (SLE)
• Polymyositis with Rheumatoid Arthritis (RA)
• Polymyositis with Systemic Sclerosis
• Polymyositis with Mixed Connective Tissue Disease (MCTD)

7. Polymyositis Market Regional And Country Analysis

• 7.1. Global Polymyositis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Polymyositis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Polymyositis Market

• 8.1. Asia-Pacific Polymyositis Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Polymyositis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Polymyositis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Polymyositis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Polymyositis Market

• 9.1. China Polymyositis Market Overview
• 9.2. China Polymyositis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Polymyositis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Polymyositis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Polymyositis Market

• 10.1. India Polymyositis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Polymyositis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Polymyositis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Polymyositis Market

• 11.1. Japan Polymyositis Market Overview
• 11.2. Japan Polymyositis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Polymyositis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Polymyositis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Polymyositis Market

• 12.1. Australia Polymyositis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Polymyositis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Polymyositis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Polymyositis Market

• 13.1. Indonesia Polymyositis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Polymyositis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Polymyositis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Polymyositis Market

• 14.1. South Korea Polymyositis Market Overview
• 14.2. South Korea Polymyositis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Polymyositis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Polymyositis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Polymyositis Market

• 15.1. Western Europe Polymyositis Market Overview
• 15.2. Western Europe Polymyositis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Polymyositis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Polymyositis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Polymyositis Market

• 16.1. UK Polymyositis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Polymyositis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Polymyositis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Polymyositis Market

• 17.1. Germany Polymyositis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Polymyositis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Polymyositis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Polymyositis Market

• 18.1. France Polymyositis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Polymyositis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Polymyositis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Polymyositis Market

• 19.1. Italy Polymyositis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Polymyositis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Polymyositis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Polymyositis Market

• 20.1. Spain Polymyositis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Polymyositis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Polymyositis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Polymyositis Market

• 21.1. Eastern Europe Polymyositis Market Overview
• 21.2. Eastern Europe Polymyositis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Polymyositis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Polymyositis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Polymyositis Market

• 22.1. Russia Polymyositis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Polymyositis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Polymyositis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Polymyositis Market

• 23.1. North America Polymyositis Market Overview
• 23.2. North America Polymyositis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Polymyositis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Polymyositis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Polymyositis Market

• 24.1. USA Polymyositis Market Overview
• 24.2. USA Polymyositis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Polymyositis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Polymyositis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Polymyositis Market

• 25.1. Canada Polymyositis Market Overview
• 25.2. Canada Polymyositis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Polymyositis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Polymyositis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Polymyositis Market

• 26.1. South America Polymyositis Market Overview
• 26.2. South America Polymyositis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Polymyositis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Polymyositis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Polymyositis Market

• 27.1. Brazil Polymyositis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Polymyositis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Polymyositis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Polymyositis Market

• 28.1. Middle East Polymyositis Market Overview
• 28.2. Middle East Polymyositis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Polymyositis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Polymyositis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Polymyositis Market

• 29.1. Africa Polymyositis Market Overview
• 29.2. Africa Polymyositis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Polymyositis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Polymyositis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Polymyositis Market Competitive Landscape And Company Profiles

• 30.1. Polymyositis Market Competitive Landscape
• 30.2. Polymyositis Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Polymyositis Market Other Major And Innovative Companies

• 31.1. GlaxoSmithKline plc
• 31.2. Merck & Co. Inc.
• 31.3. C.H. Boehringer Sohn AG & Co. KG
• 31.4. Regeneron Pharmaceuticals Inc.
• 31.5. Astellas Pharma Inc.
• 31.6. Fresenius SE & Co. KGaA
• 31.7. UCB S.A.
• 31.8. Reliance Life Sciences Private Limited
• 31.9. ARUP Laboratories
• 31.10. Teva Pharmaceuticals USA Inc.
• 31.11. Kezar Life Sciences Inc.
• 31.12. Argenx SE
• 31.13. Mallinckrodt Pharmaceuticals plc
• 31.14. Mitsubishi Tanabe Pharma Corporation
• 31.15. ViiV Healthcare Limited

32. Global Polymyositis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Polymyositis Market

34. Recent Developments In The Polymyositis Market

35. Polymyositis Market High Potential Countries, Segments and Strategies

• 35.1 Polymyositis Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Polymyositis Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Polymyositis Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer